Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
CENTAAdvancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
August 12, 2025Earnings
Read more →